Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Study’s final report confirms letrozole’s benefit for breast cancer patients


Aromatase inhibitor improves survival for some patients, reduces metastasis

The complete analysis of data from an international trial of the drug letrozole (Femara) confirms earlier reports that the drug reduced the recurrence of breast cancer in women previously treated with tamoxifen. It also finds that letrozole prevents the development of metastases, even in women whose cancer had originally spread to their lymph nodes. The report appears in the September 7 issue of the Journal of the National Cancer Institute.

"The most important new findings we describe in this article are that letrozole treatment can improve the survival of women with node-positive disease and can reduce the chance that metastatic tumors will develop," says Paul E. Goss, MD, PhD, who led the investigation. At the study’s outset, Goss was with the Princess Margaret Hospital in Toronto; he now is director of Breast Cancer Research at Massachusetts General Hospital Cancer Center.

Letrozole is one of a class of drugs called aromatase inhibitors that suppress the production of estrogen. Estogen stimulates the growth of breast tumors that express the estrogen receptor, and drugs that block the production or the action of the hormone are used in the treatment of those tumors. The most widely used estrogen-blocking drug is tamoxifen, which becomes ineffective after five years of treatment, probably because tumor cells become resistant to or even dependent on the drug.

The international study, called the MA.17 trial, was conducted through the National Cancer Institute of Canada and designed to test whether letrozole could reduce tumor recurrence and increase survival in postmenopausal breast cancer patients who had completed five years of tamoxifen treatment. More than 5,000 women were enrolled and randomly assigned to receive either letrozole or a placebo for an additional five years. The study was halted in October 2003 – four years after it began – when an interim data analysis showed that the tumors of women taking letrozole were significantly less likely recur. Those results were published in the November 6, 2003 New England Journal of Medicine.

The current report analyzes all the data compiled during the MA.17 trial and confirms that the risk of recurrence was almost 5 percent lower in those receiving letrozole than in the placebo group. Women receiving the drug also had a 39 percent reduction in the risk of metastasis. While overall survival differences between the two groups were not significant, among women whose tumors had spread to their lymph nodes and those who had received tamoxifen for more than five years, letrozole was associated with significantly better overall survival.

Although participants taking letrozole did have a greater incidence of osteoporosis, there was no significant difference in reported fractures. There was also no increased risk of cardiovascular problems, which Goss says is particularly noteable. "A recent trial comparing letrozole to tamoxifen found that letrozole might be associated with heart problems. But our study, the only placebo-controlled trial of an aromatase inhibitor, found no such association. A possible explanation of the earlier study was that tamoxifen may actually protect against cardiovascular disease, which our results support."

Goss adds that current and future studies will investigate two key questions about letrozole and other aromatase inhibitors – how long treatment should continue and whether the drugs also can benefit women who previously stopped taking tamoxifen or never took that drug. One trial that has already begun will continue following the women who received letrozole throughout the MA.17 trial and re-randomize them to receive either letrozole or a placebo for an additional five years. Another study will examine tumor samples from all MA.17 trial participants to search for molecular fingerprints that might identify who would most benefit from letrozole treatment.

Emily Parker | EurekAlert!
Further information:

More articles from Studies and Analyses:

nachricht Diagnoses: When Are Several Opinions Better Than One?
19.07.2016 | Max-Planck-Institut für Bildungsforschung

nachricht High in calories and low in nutrients when adolescents share pictures of food online
07.04.2016 | University of Gothenburg

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Etching Microstructures with Lasers

Ultrafast lasers have introduced new possibilities in engraving ultrafine structures, and scientists are now also investigating how to use them to etch microstructures into thin glass. There are possible applications in analytics (lab on a chip) and especially in electronics and the consumer sector, where great interest has been shown.

This new method was born of a surprising phenomenon: irradiating glass in a particular way with an ultrafast laser has the effect of making the glass up to a...

Im Focus: Light-driven atomic rotations excite magnetic waves

Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion

Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Ice shelf vibrations cause unusual waves in Antarctic atmosphere

25.10.2016 | Earth Sciences

Fluorescent holography: Upending the world of biological imaging

25.10.2016 | Power and Electrical Engineering

Etching Microstructures with Lasers

25.10.2016 | Process Engineering

More VideoLinks >>>